Alexion buying Portola for $18/share

• "Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care," says Alexion (NASDAQ:ALXN) CEO Ludwig Hantson.
• The $18 per share all-cash deal is more than double Portola's (NASDAQ:PTLA) close last night of $7.76. It's set to close in Q3.
• A conference call to discuss is set for 8 ET.